Checkpoint Inhibitor Therapy

The addition of immune checkpoint inhibitor therapy to neoadjuvant chemotherapy improved pathologic complete response and EFS for certain patients with early-stage breast cancer, according to a systematic review and meta-analysis.

Certain individuals with non-cell lung cancer who experienced immune-related adverse events due to immune checkpoint inhibitor therapy had improved survival outcomes, according to retrospective study data published in JAMA Network Open.

Tumor mutational burden may help predict benefit of immune checkpoint inhibitor therapy for men with metastatic castration-resistant prostate cancer, according to retrospective study results.

Indications for the use of checkpoint inhibitors are ever expanding. However, even as these drugs have helped patients with cancer live longer, the emergence of various immune related adverse events limits their full potential in many.

The cutaneous toxicities associated with cancer checkpoint inhibitors were varied depending on the malignancy and checkpoint inhibitor used, according to a study.

A triple-therapy combination extended OS compared with historical data among certain patients with advanced HPV-positive cancers, according to one of the agent’s manufacturers.

Immune checkpoint inhibitor therapy appeared associated with an increased risk for major adverse cardiovascular events among patients with cancer and a prior history of cardiovascular disease, according to results of a retrospective study.

More thorough understanding of giant cell arteritis disease processes has shed light on how immune checkpoint inhibitors may be exacerbating this and other immune-mediated conditions, according to a presenter here.